Despite recent advancements in the treatment of hematologic malignancies and the
emergence of newer and more sophisticated therapeutic approaches such as …

Introduction: Cancer cells have increased glycolysis and glutaminolysis. Their third feature is
increased de novo lipogenesis. As such, fatty acid (FA) synthesis enzymes are over …

The traditional view is that cancer cells predominately produce ATP by glycolysis, rather
than by oxidation of energy-providing substrates. Mitochondrial uncoupling—the continuing …

Many types of cancer cells require a supply of fatty acids (FA) for growth and survival, and
interrupting de novo FA synthesis in model systems causes potent anticancer effects. We …

Like most other types of cancer cells, leukaemia cells undergo metabolic reprogramming to
support rapid proliferation through enhancing biosynthetic processes. Pentose phosphate …

Chronic lymphocytic leukemia (CLL) is caused by the accumulation of malignant B cells due
to a defect in apoptosis and the presence of small population of proliferating cells principally …

Metabolic reprogramming, fundamentally pivotal in carcinogenesis and progression of
cancer, is considered as a promising therapeutic target against tumors. In chronic …

The clinical course of individual CLL patients is highly variable, with life expectancies
ranging from months to decades. Importantly, a significant subset of patients presents with …

Multiple myeloma is a haematological malignancy characterized by the clonal proliferation
of plasma cells. It has been proposed that targeting cancer cell metabolism would provide a …

Abstract Fatty acid synthase (EC 2.3. 1.85; FASN) is a multifunctional enzyme system that
catalyzes the formation of fatty acids from acetyl-CoA, malonyl-CoA, and NADPH and plays …